GSK Plc Form 6-K Summary
Business Context and Reporting Period
This Form 6-K filing by GSK Plc, dated October 1, 2025, serves as a notification to the market regarding the Company's total voting rights and capital structure. The report is filed in conformity with the Financial Conduct Authority's Disclosure Guidance and Transparency Rule 5.6.1R. The data reflects the Company's issued share capital as of September 30, 2025.
Key Financial Metrics
The filing does not provide financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on capital structure and voting rights.
| Metric | Value |
|---|---|
| Issued Ordinary Shares (31 pence each) | 4,315,407,340 |
| Treasury Shares | 247,769,844 |
| Total Voting Rights | 4,067,637,496 |
Material Changes
The filing text does not provide comparative data against a prior period to identify material changes in share capital or voting rights.
Guidance, Outlook, and Risks
This document contains no management commentary, forward-looking guidance, risk factors, contingencies, or discussion of unusual items. It is a statutory notification of share capital figures intended to assist shareholders in calculating disclosure thresholds under FCA rules.
Key Facts for Investor Verification
- Verify the total number of voting rights (4,067,637,496) against the Company's latest annual report to confirm the denominator for ownership disclosure calculations.
- Confirm the number of shares held in Treasury (247,769,844) to understand the difference between issued capital and voting capital.
- Note that this filing does not contain financial results; investors should refer to Form 20-F or quarterly earnings releases for performance data.